Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma

Shanghai Jiao Tong University School of Medicine

Status: Unknown

Conditions: Cholangiocarcinoma of the Bile Duct

Study type: Observational

Funder types: Other

Identifiers

NCT04305288

CCA20191021

Details and patient eligibility

About

The aim of this study was to evaluate the effectiveness of modified FOLFIRINOX (mFOLFIRINOX) compared to that of gemcitabine plus oxaliplatin (Gemox) for patients with locally advanced or metastatic CCA

Full description

The aim of this study was to evaluate the effectiveness of modified FOLFIRINOX (mFOLFIRINOX) compared to that of gemcitabine plus oxaliplatin (Gemox) for patients with locally advanced or metastatic CCA

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

The inclusion criteria included: patients aged 18-70 years old, regardless of gender; patients with locally advanced or metastatic CCA diagnosed by imaging and pathology; modified FOLFIRINOX regimen or Gemox regimen as first-line treatment; ≥ 1 focus that can be evaluated by imaging examination.

Exclusion criteria included: incomplete clinical history data; suffering from other malignant tumors within 5 years, except basal cell carcinoma and cervical carcinoma in situ; having received other systemic chemotherapy, targeted therapy, immunotherapy or radiotherapy as first-line treatment; with severe organ dysfunction.

Trial design

100 participants in 2 patient groups

Gemox

Description:

The patients received conventional chemotherapy Gemox

mFOLFIRINOX

Description:

The patients received chemotherapy modified FOLFIRINOX